LENZ Therapeutics addresses FAERS report of retinal tear in VIZZ patient with pre-existing risk factors

LENZ Therapeutics, Inc.

FAERS report describes retinal tear in a patient using VIZZ (aceclidine ophthalmic solution) 1.44%.
Patient had significant retinal pathology history: lattice degeneration, prior laser, previous tear; no recent peripheral exam.
Independent retina specialists note multiple pre-existing risk factors making spontaneous retinal events more likely.
Company states this initial report does not alter current safety expectations for VIZZ.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.